SBIR/STTR Research Award
Genetic Designs for High-Efficiency Macrolide Production
Award amount
$749,941Program and phase
SBIR · Phase IIAward year
1995Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- FERMALOGIC, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
The macrolides are microbial natural products with many uses in clinical and veterinary medicine. Erythromycin is the best studied example of a macrolide antibiotic; rapamycin and FK506 are promising new immunosuppressant macrolides. The price and availability of macrolides depend on their production efficiency, and therefore, on the genetics of the producing strain. Recently, university studies have shown that increasing copy-number of regulatory antibiotic genes dramatically increases the level of production of model antibiotic compounds. FermaLogic scientists are familiar with the tools required to perform analogous experiments in macrolide-producing organisms. In Phase I, we will identify and overexpress positive regulators of macrolide production. In Phase II, we will block competing metabolic pathways and negative regulators using targeted insertion mutations. Ultimately, we will create a collection of yield-improvement products and license them separately to client organizations or combine them into a single FermaLogic strain for high-level macrolide production.
Technology keywords
Not reported